Zobrazeno 1 - 10
of 81
pro vyhledávání: '"Hiroyuki, Ohbayashi"'
Autor:
Takamitsu Asano, Hiroyuki Ohbayashi, Mitsue Ariga, Osamu Furuta, Sahori Kudo, Junya Ono, Kenji Izuhara
Publikováno v:
ERJ Open Research, Vol 6, Iss 2 (2020)
Introduction Dynamic hyperinflation (DH) is sometimes observed and is associated with impaired daily life activities of asthma. We assessed the relationship between DH and asthma biomarkers (blood eosinophil, fractional exhaled nitric oxide (FeNO) an
Externí odkaz:
https://doaj.org/article/753e7eb45a564a08b18e48a122ac2d3b
Publikováno v:
Pulmonary Therapy, Vol 4, Iss 2, Pp 159-169 (2018)
Abstract Introduction Products based on inhaled corticosteroid (ICS)/long-acting β2 agonist (LABA) combinations may provide different clinical benefits. This study was conducted to compare the rapid effects of three such combination products: formot
Externí odkaz:
https://doaj.org/article/e0181a45f50246c8a751a5fa8570b39e
Autor:
Hiroyuki, Ohbayashi, Yasuo, Sato, Mari, Kiuchi, Atsushi, Nagazumi, Takumi, Kanzo, Takazumi, Kimura
Publikováno v:
Expert Review of Gastroenterology & Hepatology. 16:809-817
To compare outcomes between two doses of lubiprostone in patients with chronic constipation (CC), to assess whether dose reduction affects efficacy.This open-label exploratory study involved 146 patients with CC treated initially with lubiprostone 24
Autor:
Takamitsu Asano, Atsushi Nagazumi, Hiroyuki Ohbayashi, Mari Kiuchi, Takazumi Kimura, Yasuo Sato
Publikováno v:
Expert Review of Gastroenterology & Hepatology. 15:333-342
To investigate the continuation rate with a reduced lubiprostone dose (12 mcg twice daily, BD) after the onset of adverse events (AEs) in patients with chronic constipation (CC).In this exploratory, open-label, multicenter study, patients with CC rec
Autor:
Tetsuri, Kondo, Toshimori, Tanigaki, Makoto, Hibino, Sakurako, Tajiri, Shigeru, Horiuchi, Hiroyuki, Ohbayashi
Publikováno v:
Arerugi = [Allergy]. 71(1)
Recently, BudeForuAn inhalation simulator generated either ramp-up or triangular (time to reach peak inhaling flow (PIF) = 0.42 s) inhalation pattern. Time trajectories of inhaled flow and released particles from either device were depicted with a ph
Autor:
Hiroyuki Ohbayashi, Kenji Izuhara, Mitsue Ariga, Takamitsu Asano, Sahori Kudo, Junya Ono, Osamu Furuta
Publikováno v:
ERJ Open Research
article-version (VoR) Version of Record
ERJ Open Research, Vol 6, Iss 2 (2020)
article-version (VoR) Version of Record
ERJ Open Research, Vol 6, Iss 2 (2020)
Introduction Dynamic hyperinflation (DH) is sometimes observed and is associated with impaired daily life activities of asthma. We assessed the relationship between DH and asthma biomarkers (blood eosinophil, fractional exhaled nitric oxide (FeNO) an
Publikováno v:
Allergology International, Vol 59, Iss 4, Pp 355-362 (2010)
Background: To reduce deaths from asthma, further use of inhaled corticosteroids (ICS) in accordance with the guidelines is required. The present study was conducted because specialists are responsible for increasing the use of guidelines, but the cu
Externí odkaz:
https://doaj.org/article/76591dbbb78d42488e2f9ef86aadb4b7
Autor:
Hiroyuki Ohbayashi, Mitsuru Adachi
Publikováno v:
Allergology International, Vol 57, Iss 3, Pp 231-239 (2008)
Background: To evaluate whether hydrofluoroalkane-beclomethasone dipropionate (HFA-BDP) controls eosinophilic inflammation, including that in the distal airways, more effectively than fluticasone propionate (FP) Diskus®. Methods: Fifty patients with
Externí odkaz:
https://doaj.org/article/9a24e756fb9240988cd1b77fb683718f
Autor:
Hiroyuki Ohbayashi
Publikováno v:
Allergology International, Vol 54, Iss 3, Pp 411-418 (2005)
Background: Fluticasone propionate (FP) Diskus® is generally regarded as an easy to use and efficacious inhaled device. This study clinically evaluated whether its easy handling and inhalation process were affected by the aging factor or not, compar
Externí odkaz:
https://doaj.org/article/fd54c85390684854aa18637aacbb75c4
Autor:
Hiroyuki Ohbayashi
Publikováno v:
Allergology International, Vol 54, Iss 4, Pp 633-637 (2005)
Background: Pranlukast and Montelukast are Cysteinyl leukotriene receptor antagonists with almost the same pharmacological activity. However, I will describe a case in which these drugs showed different therapeutic effects on clinical symptoms during
Externí odkaz:
https://doaj.org/article/f2e219ef391c4853a285289f7741926a